Windlas Biotech Limited is a leading pharmaceutical company specializing in generic formulations, trade generics, and CDMO services. With robust 19% YoY revenue growth reported, the company showcases strong operational performance and strategic execution across its core verticals.

The expansion of Plant-2 and ongoing Plant-6 developments signify its commitment to enhancing production capabilities, targeting long-term growth. Notably, the company's diversified revenue streams span top-tier pharmaceutical partnerships across its business verticals.

Windlas Biotech maintains a sophisticated R&D infrastructure that propels innovation in complex generic product development, showcasing its aptitude for advanced pharmaceutical solutions.

A proactive ESOP scheme aligns corporate goals with talent retention, rewarding 100 employees to sustain growth momentum and operational excellence.